BacteriaCardiovascular Science and Diabetes ProgramEmergency MedicineKidney DiseaseMedia ReleasesNews & EventsSynthetic Biology and Drug DiscoveryTargeted Drug DeliveryTranslation
Antibiotics resistance solution to be commercialised
By Richard Schoonraad | Bacteria, Cardiovascular Science and Diabetes Program, Emergency Medicine, Kidney Disease, Media Releases, News & Events, Synthetic Biology and Drug Discovery, Targeted Drug Delivery, TranslationBreakthrough diagnostic technology to be commercialised in Australia in race to save millions globally from antibiotic resistant sepsis. CUREator funds Western Australian research team to develop life-saving technology through the…
Biomedical engineeringBlood VesselsCardiovascular DiseaseCardiovascular DiseaseCardiovascular Science and Diabetes ProgramChronic Kidney DiseaseDisease AreaKidney DiseaseKidneysMedia ReleasesNews & EventsVascular Engineering
Tiny filters with big roles for patients with chronic kidney disease
By Alicia Bienkowski | Biomedical engineering, Blood Vessels, Cardiovascular Disease, Cardiovascular Disease, Cardiovascular Science and Diabetes Program, Chronic Kidney Disease, Disease Area, Kidney Disease, Kidneys, Media Releases, News & Events, Vascular EngineeringPerth bioengineers investigate critical device for dialysis machines Fast facts An estimated 1.7 million or 10% of Australian adults have Chronic Kidney Disease (CKD) An estimated 1 in 5 or…
Chronic Kidney DiseaseFundingKidney DiseaseKidneysMedia ReleasesMolecular Endocrinology and PharmacologyMolecular MedicineNews & EventsResearch Area
$20M for biopharm DIMERIX to fund phase 3 trials for rare kidney disease
By Alicia Bienkowski | Chronic Kidney Disease, Funding, Kidney Disease, Kidneys, Media Releases, Molecular Endocrinology and Pharmacology, Molecular Medicine, News & Events, Research AreaBiopharmaceutical company, Dimerix (ASX: DXB), which is developing new treatments for types of inflammatory kidney and respiratory diseases, announced it has successfully raised $20 million to fund Phase 3 trials…